Answer
The most commonly reported adverse reactions to intravenous vedolizumab are infections (such as nasopharyngitis, upper respiratory tract infection, bronchitis, influenza and sinusitis), headache, nausea, pyrexia, fatigue, cough and arthralgia.
Sources for this answer
- Entyvio 300 mg powder for concentrate for solution for infusionTakeda UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 17Document updated
Sources checked